4SC AG / Capital Increase 20.06.2008 Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Planegg-Martinsried, Germany, 20 June 2008 Today, the Management Board of the Martinsried-based drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC), with the approval of the Supervisory Board, decided to increase the share capital from 19,001,826.00 Euros to up to 28,502,739.00 Euros, by issuing up to 9,500,913 zero par value common bearer shares from the authorised capital. The new shares are to be offered to the shareholders at a subscription price of 3.10 Euros per new share. The proceeds of the capital increase are to be used for financing the acquisition of Nycomeds oncology projects in the amount of 14 million Euros (compare Ad Hoc announcement of 4SC AG dated 4 June 2008) and to further develop the existing as well as the new project pipeline of 4SC AG. The subscription rights of the shareholders are complied with. The shareholders can subscribe to the new shares with dividend rights from 1 January 2008 in a 2:1 ratio starting from 25 June 2008 until 10 July 2008. In the following unsubscribed shares are to be offered to institutional investors. A public offer for the purchase of the new shares is not planned. The admission of the new shares for trading at the Frankfurt Stock Exchange is not expected before November/December 2008. Further details of the capital increase will be provided in the subscription offer expected to be published in the electronic Federal Gazette on 25 June 2008. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: About 4SC AG: 4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with a staff of 74, the company develops novel drug candidates for inflammatory diseases, cancer and infectious diseases using a cheminformatics based technology platform. Traditional high throughput screening of therapeutic agents has been transferred from the lab to the computer. Thus, the company offers substantial cost and time advantages as well as increased success rates in drug development. 4SC AG utilises its technology platform, which is protected by patent, to create a sustainable project pipeline of active agents to be developed up to the early clinical phases ('proof of concept') and subsequently licensed to the pharmaceutical industry in return for advance and milestone payments as well as royalties. There are currently six projects in the pipeline and a so-called ideas pool with further development candidates. The first project for the treatment of rheumatoid arthritis has already successfully completed clinical phase IIa. Four other product candidates are in pre-clinical development and another project is in the research stage. In addition, the company is implementing its technology platform in partnerships with pharmaceutical and biotechnology companies, and is already generating initial revenues. Legal Note This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors. Bettina von Klitzing Manager Investor Relations & Public Relations 4SC AG Tel.: +49 (0) 89 70 07 63 - 0 Bettina.von.Klitzing@4sc.com DGAP 20.06.2008 --------------------------------------------------------------------------- Language: English Issuer: 4SC AG Am Klopferspitz 19a 82152 Martinsried Deutschland Phone: +49 (0)89 7007 63-0 Fax: +49 (0)89 7007 63-29 E-mail: public@4sc.com Internet: www.4sc.de ISIN: DE0005753818 WKN: 575381 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: 4SC AG decides on an increase in share capital
| Source: EQS Group AG